Pfizer Inc (PFE)

PFE on New York Consolidated

30.10USD
28 Jul 2014
Price Change (% chg)

$-0.09 (-0.30%)
Prev Close
$30.19
Open
$29.79
Day's High
$30.17
Day's Low
$29.78
Volume
25,504,692
Avg. Vol
26,468,515
52-wk High
$32.96
52-wk Low
$27.76

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.68
Market Cap (Mil.): $192,377.70
Shares Outstanding (Mil.): 6,372.23
Dividend: 0.26
Yield (%): 3.44

Financials

  PFE Industry Sector
P/E (TTM): 18.41 35.64 36.09
EPS (TTM): 1.64 -- --
ROI: 7.23 18.92 18.19
ROE: 13.79 19.68 19.06
Search Stocks

Pfizer's need for deal looms larger with earnings report

NEW YORK - Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

1:36am EDT

AstraZeneca results to get lift from bid foe Pfizer

LONDON - AstraZeneca has the chance next week to showcase its financial resilience after resisting a $118 billion takeover bid from Pfizer - and, ironically, it will get a helping hand from its U.S. foe.

25 Jul 2014

CORRECTED-UPDATE 2-Lilly beats forecasts, vows to remain independent

(Corrects 10th paragraph to show Pfizer bought Warner Lambert, Pharmacia and Wyeth (not Pfizer)

24 Jul 2014

CORRECTED-Shire, AbbVie to announce $53 billion merger by Friday -sources

(Corrects 6th paragraph to show Pfizer's failed bid for AstraZeneca happened in May not June)

17 Jul 2014

Salix joins up with Cosmo Pharma's Irish unit for tax savings

ZURICH - Swiss-listed Cosmo Pharmaceuticals said on Wednesday it would merge its Irish subsidiary with U.S. firm Salix Pharmaceuticals , the latest in a wave of overseas deal-making by U.S. companies looking to lower their tax bill.

09 Jul 2014

Pfizer wins dismissal of U.S. investor class action ahead of trial

NEW YORK - Pfizer Inc won the dismissal Tuesday of a long-running shareholder class action accusing the company of misleading investors about the safety of its Celebrex and Bextra pain-relieving drugs.

08 Jul 2014

Pfizer wins dismissal of U.S. investor class action ahead of trial

NEW YORK, July 8 - Pfizer Inc won the dismissal Tuesday of a long-running shareholder class action accusing the company of misleading investors about the safety of its Celebrex and Bextra pain-relieving drugs.

08 Jul 2014

AbbVie presses case for Shire deal in discreet roadshow

* U.S. drugmaker urges deal in talks with Shire shareholders

03 Jul 2014

UPDATE 5-Destination Maternity keen to buy UK's Mothercare

* 2nd proposal worth 266 mln stg would involve tax inversion

02 Jul 2014

Destination Maternity keen to buy UK's Mothercare

LONDON - U.S. baby product retailer Destination Maternity will continue its pursuit of Britain's Mothercare after revealing on Wednesday it had two bid proposals rejected.

02 Jul 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $102.11 0.00
Novartis AG (NOVN.VX) CHF79.40 -0.55
Merck & Co., Inc. (MRK.N) $57.97 -0.18
Roche Holding Ltd. (ROG.VX) CHF265.50 -1.50
Abbott Laboratories (ABT.N) $42.93 -0.11
Bayer AG (BAYGn.DE) €99.29 +0.58
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.33 +0.35
AstraZeneca plc (AZN.L) 4,361.00p -31.00
GlaxoSmithKline plc (GSK.L) 1,414.50p -8.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks